Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sleep Coach for Adolescents With Type 1 Diabetes
NCT06516614
Recruiting
The goal of this work is to conduct a randomized trial evaluating the effects of a behavioral intervention to increase sleep duration and quality for adolescents with type 1 diabetes (T1D). The impact of the sleep-promoting intervention on executive function and glycemic outcomes will be assessed. We will also explore multiple components of the recently identified central nervous system glymphatic system and evaluate how these components change and impact brain integrity and function with improv... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
09/19/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Type 1 Diabetes
Register for Updates
Assessment of the Ocular Microbiome in Health and Disease
NCT05414994
Recruiting
The objective of this application is to illustrate the core constituents of the ocular surface microbiome, describe factors that promote colonization, and assess the ocular microbiome's role in the health of the anterior segment. We will conduct a prospective, observational cohort study, including a longitudinal analysis of the ocular microbiome in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Microbial Colonization, Eye Diseases, Ophthalmopathy
Register for Updates
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
NCT05996432
Recruiting
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Head and Neck Squamous Cell Carcinoma, Brain Metastases
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Neuroblastoma
Register for Updates
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795
Recruiting
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Site USA07-0, Nashville, Tennessee
Conditions: Solid Tumor, Adult
Register for Updates
Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma
NCT04561206
Recruiting
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune sys... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Relapsed Classic Hodgkin Lymphoma
Register for Updates
Academic-Community EPINET (AC-EPINET)
NCT04497857
Recruiting
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
Gender:
ALL
Ages:
Between 16 years and 35 years
Trial Updated:
09/17/2024
Locations: Vanderbilt's Early Psychosis Program - Vanderbilt University, Nashville, Tennessee
Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Register for Updates
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
NCT01885299
Recruiting
The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2024
Locations: Cyberknife at Erlanger, Chattanooga, Tennessee
Conditions: Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
Register for Updates
Next Generation Rocklatan
NCT06441643
Recruiting
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: University Eye Specialists, Maryville, Tennessee
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
Ansa Cervicalis and Hypoglossal Nerve Stimulation in OSA
NCT05501236
Recruiting
Polysomnography (PSG) and drug-induced sleep endoscopy (DISE) are widely used diagnostic studies for assessing obstructive sleep apnea (OSA) severity and collapse patterns of the upper airway anatomy during sleep. Hypoglossal nerve stimulation (HNS) therapy for obstructive sleep apnea suffers from variable response at the level of the soft palate. The Investigators propose a study examining the physiologic effect of ansa cervicalis stimulation (ACS) alone and in combination with HNS during PSG a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Obstructive Sleep Apnea
Register for Updates
Cooperative Assessment of Late Effects for SCD Curative Therapies
NCT05153967
Recruiting
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened.... Read More
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
09/16/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Sickle Cell Disease, Pulmonary Disease, Renal Disease, Heart Disease
Register for Updates
Activity Monitoring in Pulmonary Hypertension
NCT04101630
Recruiting
This is a prospective, longitudinal, observational study of free-living activity trackers and patient reported outcomes to test the hypothesis that daily activity will have stronger prognostic value than 6MWD in patients with pulmonary hypertension after 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Pulmonary Hypertension
Register for Updates